<DOC>
	<DOCNO>NCT01941329</DOCNO>
	<brief_summary>This study prospective , randomize , multicentre , open label study intent compare efficacy safety ranibizumab 0.5 mg Intravitreal ( ITV ) injection plus Panretinal Photocoagulation versus Panretinal Photocoagulation alone regression neovascularization area patient High Risk Proliferative Diabetic Retinopathy 12-month treatment period . One major complication diabetes mellitus Diabetic Retinopathy ( DR ) , one lead cause visual impairment work age industrialized country . Longer diabetes duration poor glycaemic blood pressure control strongly associate Diabetic Retinopathy . The overall prevalence form Diabetic Retinopathy 34.4 % 6.96 % corresponds Proliferative Diabetic Retinopathy ( PDR ) . Therefore , approximately 93 million people Diabetic Retinopathy 17 million Proliferative Diabetic Retinopathy . It show treatment repeat injection ranibizumab improve visual acuity patient PDR . Further , , standard PRP treatment PDR remain unsatisfactory . The knowledge mechanisms retinal complication incomplete , therefore , effort do understand characterize patient ' eye response combine treatment . Therefore , purpose study compare standard treatment PDR ( i.e . Panretinal Photocoagulation ) Panretinal Photocoagulation treatment combine ITV injection ranibizumab since expect anti-vascular endothelial growth factor ( VEGF ) treatment ITV injection increase rate success Panretinal Photocoagulation regression neovascularization improve final visual acuity .</brief_summary>
	<brief_title>Prospective , Randomized , Multicentre , Open-label , Phase II / III Study Assess Efficacy Safety Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation ( PRP ) Versus PRP Monotherapy Treatment Subjects With High Risk Proliferative Diabetic Retinopathy .</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Highrisk proliferative diabetic retinopathy ( HRPDR ) ; Neovascularization disc ( NVD ) ≥ 1/4 disc area ( DA ) OR Neovascularization elsewhere ( NVE ) ≥ 1/2 DA ; NVE &lt; 1/2 DA + vitreous and/or preretinal haemorrhage and/or rubeosis ; NVD &lt; 1/4 DA + vitreous and/or preretinal haemorrhage and/or rubeosis ; BCVA baseline ≥ 24 Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter score ( approximate Snellen equivalent 20/320 ) ; Type I Type II diabetic subject either gender ; Age ≥ 18 year ; Ability provide write informed consent ; Ability return clinical trial visit ; Any intraocular surgery within 6 month trial enrolment , include : Prior scatter ( panretinal ) focal/grid photocoagulation ; Eyes receive yttrium aluminum garnet ( YAG ) laser , peripheral retinal cryoablation , laser retinopexy ( retinal tear ) ; Fibrovascular proliferation retinal traction ; Other cause retinal NV ( retinal vein occlusion , radiation retinopathy others ) ; Atrophy/scarring/fibrosis/ hard exudate involve centre macula ; Significant medium opacity inadequate pupillary dilation , might interfere visual acuity , assessment toxicity fundus photography ; Any likelihood subject require cataract surgery within follow 1 year ; Diabetic macular edema ( DME ) central involvement , i.e. , central macular thickness ( Central Point Thickness ) &gt; 300 µm ( Stratus OCT ) equivalent value measure spectral domain ( SD ) OCT , adjust accord SDOCT machine use ; Previous vitrectomy ; Intraocular pressure &gt; 21 mmHg ; Previous antiVEGF therapy within last 3 month ; Known serious allergy history hypersensitivity fluorescein use angiography , component Lucentis® formulation ; Acute ocular periocular infection ; Previous filter surgery ( e.g. , trabeculectomy ) placement glaucoma drainage device ( e.g. , tubeshunt surgery ) ; General Exclusion Criteria Systolic BP &gt; 170 mmHg diastolic BP &gt; 100 mmHg ; HbA1C level &gt; 11 % recent sign uncontrolled diabetes ; Any follow underlying systemic disease : History evidence severe cardiac disease , e.g . New York Heart Association ( NYHA ) Functional Class III IV , clinical medical history unstable angina , acute coronary syndrome , myocardial infarction , revascularization procedure within 6 month prior baseline , ventricular tachyarrhythmia require treatment ; History evidence clinically significant peripheral vascular disease intermittent claudication prior amputation ; Renal failure require dialysis renal transplant renal insufficiency creatinine level &gt; 2.0 mg/dl screening ; Stroke ( within 12 month trial entry ) ; Any major surgical procedure within one month trial enrolment ; Subject condition ( advanced , severe unstable disease treatment ) situation may put him/her significant risk , may confound study result may interfere significantly subject 's participation study ; Previous radiation head region study eye ; Use investigational drug within last 3 month ( DR condition ) ; History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis ; Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Proliferative Retinopathy</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Panretinal Photocoagulation</keyword>
</DOC>